ADIL Adial Pharmaceuticals Inc

2.1
-0.02  -1%
Previous Close 2.12
Open 2.1
Price To Book 2.47
Market Cap 21,668,539
Shares 10,318,352
Volume 32,219
Short Ratio
Av. Daily Volume 94,803
Stock charts supplied by TradingView

NewsSee all news

  1. Adial Pharmaceuticals Receives Approval to Commence Phase 3 Trial in Finland

    CHARLOTTESVILLE, VA / ACCESSWIRE / January 9, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced

  2. Adial Pharmaceuticals Submits Clinical Trial Applications in Six Additional European Countries

    CHARLOTTESVILLE, VA / ACCESSWIRE / December 19, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced

  3. Adial Pharmaceuticals Receives Notice of Allowance of Additional Patent for the Treatment of Alcohol Use Disorder with AD04 in Patients Identified Using a Molecular Genetic Biomarker

    CHARLOTTESVILLE, VA / ACCESSWIRE / December 16, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced

  4. Adial Completes Validation of Genetic Biomarker Test in Collaboration with Eurofins for Upcoming Phase 3 Trial

    Reports regulatory progress in Europe and imminent commencement of clinical trial CHARLOTTESVILLE, VA / ACCESSWIRE / December 13, 2019 / Adial Pharmaceuticals, Inc. ("Adial") (NASDAQ:ADIL, ADILW)), a

  5. Adial Pharmaceuticals Announces Mark Howard Peikin, Esq. as Chief Strategy Officer and VP of Corporate Communications as Adial Advances Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder

    CHARLOTTESVILLE, VA / ACCESSWIRE / October 7, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)) www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of treatments for

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial due to commence December 2019 with data due in 2021. Data from second Phase 3 trial for U.S. required endpoint due 2023.
AD04
Alcohol use disorder

Latest News

  1. Adial Pharmaceuticals Receives Approval to Commence Phase 3 Trial in Finland

    CHARLOTTESVILLE, VA / ACCESSWIRE / January 9, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced

  2. Adial Pharmaceuticals Submits Clinical Trial Applications in Six Additional European Countries

    CHARLOTTESVILLE, VA / ACCESSWIRE / December 19, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced

  3. Adial Pharmaceuticals Receives Notice of Allowance of Additional Patent for the Treatment of Alcohol Use Disorder with AD04 in Patients Identified Using a Molecular Genetic Biomarker

    CHARLOTTESVILLE, VA / ACCESSWIRE / December 16, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced

  4. Adial Completes Validation of Genetic Biomarker Test in Collaboration with Eurofins for Upcoming Phase 3 Trial

    Reports regulatory progress in Europe and imminent commencement of clinical trial CHARLOTTESVILLE, VA / ACCESSWIRE / December 13, 2019 / Adial Pharmaceuticals, Inc. ("Adial") (NASDAQ:ADIL, ADILW)), a

  5. Adial Pharmaceuticals Announces Mark Howard Peikin, Esq. as Chief Strategy Officer and VP of Corporate Communications as Adial Advances Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder

    CHARLOTTESVILLE, VA / ACCESSWIRE / October 7, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)) www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of treatments for

  6. Adial Provides Update on Clinical Activities; Filing to Commence Phase 3 Trial on Track for Q3 2019

    CHARLOTTESVILLE, VA / ACCESSWIRE / September 25, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today provided

  7. Adial Pharmaceuticals Announces Successful Product Retesting of AD04 for Phase 3 Clinical Trial

    CHARLOTTESVILLE, VA / ACCESSWIRE / September 11, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (NASDAQ:ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today

  8. Adial Pharmaceuticals Completes Key Regulatory Milestone Prior to Commencing European Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder

    Application for pediatric investigation plan waiver validated by European Medicines Agency CHARLOTTESVILLE, VA / ACCESSWIRE / September 5, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)), a clinical-stage